Canada Markets close in 5 hrs 5 mins

Atai Life Sciences N.V. (ATAI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
10.73+0.15 (+1.42%)
As of 10:53AM EST. Market open.
Full screen
Loading interactive chart...
  • GlobeNewswire

    atai Life Sciences Increases its Ownership Position in COMPASS Pathways

    Demonstrates atai’s confidence in COMPASS’ Phase 2b data and its potential for patients with treatment-resistant depression Reinforces COMPASS as highly complementary to atai’s diversified approach to innovation in mental health NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it has increased its ownership interest in COMPASS Pathwa

  • GlobeNewswire

    atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate Update

    -Positive topline results from COMP360’s Phase 2b study- -RL-007 Phase 2a topline data in cognitive impairment associated with schizophrenia expected end of Q4- -Continued progress across 11 therapeutic programs, including initiation of Perception’s Phase 2a and DemeRx’s Phase 1/2 trials as well as interim Phase 2a RL-007 readout of first cohort- -Launch of atai Impact, a philanthropic program to harness the power of innovative mental health approaches for social change- -Company to host a webca

  • GlobeNewswire

    atai Life Sciences to Host Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Business Update

    NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a conference call on Monday, November 15, 2021 at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30, 2021 and provide a business update. To access the live conference call, please dial 877-407-3982 from the United States, or +1 (201)